Biosensors Technology at Euro PCR 2016
|
|
- Emerald Murphy
- 6 years ago
- Views:
Transcription
1 Biosensors Technology at Euro PCR 2016 Location and timing are subject to change based on the EuroPCR 2016 program
2 Tuesday 17 May Hot Line 11:20-11:28 Main Arena BioFreedom / LEADERS FREE Late-breaking trials, registries and innovations C.K. Naber Biolimus BA9 drug-coated stent vs. bare metal-stent in patients presenting with ACS - a prespecified LEADERS FREE ACS substudy Hot Line 15:30-15:39 մեéâtre Bordeaux BioFreedom / LEADERS FREE Late-breaking trials and trial updates in coronary interventions P. Urban մեe balance of thrombosis and bleeding in patients at high-bleeding risk from LEADERS FREE trial Hot Line 16:09-16:18 մեéâtre Bordeaux Nobori / COMPARE II Late-breaking trials and trial updates in coronary interventions P. Smits մեe final five-year results from the COMPARE II trial: the first real long-term results between biodegradable polymer biolimus-eluting stent and durable polymer everolimus-eluting stent Cases 17:28-13:36 Room 342B Axxess Bifurcation PCI: is there a place for OCT? Z. Yao Parallel coronary bifurcation treated with Axxess DES: offline 3D OCT reconstruction demonstrating stent implantation and avoidance of carina shift
3 Wednesday 18 May Plenary Session 10:30-11:30 Room Arlequin BioFreedom / LEADERS FREE Will LEADERS FREE change my practice? M. Behan Introduction - the trial headlines K.G. Oldroyd A representative case from the study: how should I treat? Discussion: what is common practice where you work? G.G. Stefanini What was known before LEADERS FREE? M. Valgimigli Trial(ist) review: methods, results, conclusions : do we need to change practice? K.G. Oldroyd Case conclusion: how does this apply to my practice? M.B. Leon Concluding remarks Abstracts 14:58-15:06 Room 353 Axxess - COBRA Mid- and long-term follow-up after bifurcation PCI J. Bennett մեree-year clinical follow-up of the COBRA (complex coronary bifurcation lesions: randomised comparison of a strategy using a dedicated self-expanding biolimus A9-eluting stent vs. a culotte strategy using everolimus-eluting stents)
4 մեursday 19 May Cases 08:56-09:04 Room Ternes 1 Left main PCI in challenging clinical situations D.A. Sinaga Hybrid polymer-free Biolimus-coated stent and drug-coated balloon angioplasty in anterior STEMI involving ostial left main disease in high bleeding risk patient Sponsored session 12:30-14:00 Room 251 BioFreedom / LEADERS FREE Case in Point From LEADERS FREE to clinical practice: a case-based approach in tailoring stent treatment to patients with or without high bleeding risk C. Tamburino Session objectives G. Richardt Case 1 - From DAPT to triple therapy, increasing the risk of bleeding D. Carrié Case 3 - Uncertain bleeding risk in the case of STEMI R. Moreno Case 4 - Coronary artery disease and severe aortic stenosis scheduled for TAVI P. Urban Session evaluation and key learnings CRO / ARO 12:35-12:42 Room 343 BioFreedom / LEADERS FREE Planned and ongoing clinical trials: a status update from Cardiovascular European Research Center (CERC) M.C. Morice LEADERS FREE: how will further planned analyses modulate the conclusions? CRO / ARO 13:39-13:49 Room 343 BioFreedom / BIOFREEDOM FIM - EGO Planned and ongoing clinical trials: a status update from Cardiovascular Research Centre (CRC) R. Costa Innovative metallic DES clinical programmes: DISCOVERY, MERIT series - IBiOSS, BIOFREEDOM FIM/EGO, REVELUTION Abstracts 16:03-16:11 Room 343 Nobori / SORT-OUT VII OCT Contemporary DES: focus on bioresorbable polymers (Part 1) L.N. Andreasen Randomised comparison of sirolimus-eluting, and biolimus-eluting bioresorbable polymer stents: մեe SORT-OUT VII OCT study
5 BioFreedom and Axxess are not available for sale in France and the information related to these products is not intended for health care professionals who practice in France. Les produits BioFreedom et Axxess ne sont pas disponibles à la vente en France et les informations les concernant ne sont pas destinées aux professionnels de la santé exerçant en France. Axxess, BioFreedom, Biolimus A9 and BA9 are trademarks or registered trademarks of Biosensors International Group, Ltd. All other cited trademarks are the property of their respective owners. Not available for sale in the United States and certain other countries Biosensors International Group, Ltd. All rights reserved.
LEADERS FREE ACS EN - Rev.01
C.K. Naber, P. Urban, P.J. Ong, M. Valdes-Chavarri, A. Abizaid, S.J. Pocock, F. Fabbiocchi, C. Dubois, S. Copt, S. Greene and M.C. Morice for the LEADERS FREE Investigators Presented by CK Naber EuroPCR
More informationTailored bifurcation therapy
Tailored bifurcation therapy Dedicated self-expanding platform that conforms to the specific bifurcation anatomy Full bifurcation lesion coverage without creating a false carina Bifurcation DES technology
More informationThe tailored solution for your bifurcation therapy
The tailored solution for your bifurcation therapy The tailored solution for your bifurcation therapy Dedicated self-expanding platform that conforms to the specific bifurcation anatomy Full bifurcation
More informationTaking DES technology from concept to long term clinical evidence. Aurore Bouvier Global Product Manager Biosensors Europe
Taking DES technology from concept to long term clinical evidence Aurore Bouvier Global Product Manager Biosensors Europe My conflicts of interest are: Full time employee of Biosensors Europe SA BA9 shows
More informationFrom a DES to a BMS* Biosensors Clinical Trial Program. Taking the LEAD in DES Clinical Excellence. From Single de Novo.
Biosensors Clinical Trial Program Taking the LEAD in DES Clinical Excellence Our trials gather clinical data for this technology from a wide range of patients, including those with single de novo lesions,
More informationMoins de 6 mois d antiagrégants après DES?
Moins de 6 mois d antiagrégants après DES? High Tech - Marseille 25 au 27 janvier 2011 Marie-Claude MORICE, MD, FESC, FACC Massy, France Pas de conflit d interet Was optimal duration of DAPT already established
More informationΕνδοςτεφανιαίεσ προκζςεισ (stents):παρόν και μζλλον. Σ Χατηθμιλτιάδθσ Αναπλθρωτισ Κακθγθτισ Πανεπιςτθμιακό Νοςοκομείο ΑΧΕΠΑ
Ενδοςτεφανιαίεσ προκζςεισ (stents):παρόν και μζλλον Σ Χατηθμιλτιάδθσ Αναπλθρωτισ Κακθγθτισ Πανεπιςτθμιακό Νοςοκομείο ΑΧΕΠΑ DES Penetration -(2011) Source: Millenium Research Group Cordis has stopped manufacturing
More informationOrbusNeich at TCT Late Breaking, Presentations and Poster Sessions
OrbusNeich at TCT Late Breaking, Presentations and Poster Sessions Booth No: 3011 MONDAY, OCTOBER 30 Special Session: 15th Anniversary HBD (Harmonization By Doing): New Synergies in Japan-U.S. Research
More informationVascular Intervention // Coronary Drug-Eluting Stent System. Orsiro. Clinically proven. Highly deliverable. Ultrathin 60 μm struts
Vascular Intervention // Coronary Drug-Eluting Stent System Clinically proven Highly deliverable Ultrathin 60 μm struts The new benchmark for DES BIOFLOW-V 12-month clinical outcomes compared to Xience
More informationPCI with Polymer-free Stent
PCI with Polymer-free Stent Florian Krackhardt, M.D. Department of Cardiology Charité Campus Virchow-Klinikum University Hospital Berlin, Germany Drug Eluting Stents: Present Coating Technology Solution
More informationFreedom to Treat Your High Bleeding Risk Patients. Tim Kinnaird University Hospital of Wales, Cardiff, UK
Freedom to Treat Your High Bleeding Risk Patients Tim Kinnaird University Hospital of Wales, Cardiff, UK Relevant Disclosures Honoraria for lectures from: o Eli Lilly & Co, Daiichi Sankyo, Boehringer,
More informationReduction in Stent Thrombosis better tablets or better stents?
Reduction in Stent Thrombosis better tablets or better stents? Dr James Cotton MD FRCP Heart and Lung Centre Wolverhampton MY CONFLICTS OF INTEREST ARE Speaker Fees/Honoraria/Travel Support Lilly/Daiichi
More informationTwo-Year Outcomes of High Bleeding Risk Patients after Polymer-Free Drug-Coated Stents
Two-Year Outcomes of High Bleeding Risk Patients after Polymer-Free Drug-Coated Stents Philip Urban, Philippe Garot, Damras Tresukosol, Stuart J. Pocock, Ian Meredith, Alex Abizaid, Didier Carrié, Christoph
More informationBiosensors Lunch Symposium
Are Current DES the Final Answer? BioFreedom TM : the Polymer-Free Biolimus A9TM Coated Stent Biosensors Lunch Symposium 25 th April 2013 Prof. Stephen WL Lee, JP 李偉聯 MD FRCP(Lon. Edin. Glas.) FHKCP FHKAM
More informationDUREE de la BITHERAPIE dans les ETUDES LEADERS. J BERLAND Clinique Saint Hilaire ROUEN
DUREE de la BITHERAPIE dans les ETUDES LEADERS J BERLAND Clinique Saint Hilaire ROUEN LEADERS all-comers Trial Design Stable and ACS Patients Undergoing PCI Assessor-blind 1:1 Randomisation N=1700 Patients
More informationDISCOVER Ultimaster with Optical Frequency Domain Imaging
DISCOVER Ultimaster with Optical Frequency Domain Imaging David Hildick-Smith Sussex Cardiac Centre Brighton and Sussex University Hospitals United Kingdom Potential conflicts of interest Speaker's name:
More informationTogether. INFINITE POSSIBILITIES.
ST. JUDE MEDICAL IS NOW ABBOTT Together. INFINITE POSSIBILITIES. Abbott and St. Jude Medical have joined together. Visit us at EuroPCR 2017. Join us at our exciting scientific sessions, and explore our
More informationKomplexe Koronarintervention heute: Von Syntax zu bioresorbierbaren Stents
Komplexe Koronarintervention heute: Von Syntax zu bioresorbierbaren Stents Prof. Dr. med. Julinda Mehilli Medizinische Klinik und Poliklinik I Klinikum der Universität München Campus Großhadern Key Factors
More informationCatch-up Phenomenon: Insights from Pathology
Catch-up Phenomenon: Insights from Pathology Michael Joner, MD CVPath Institute Inc. Gaithersburg, MD USA Path Lessons learned from the BMS and DES (1 st Gen) era Neointimal Thickness [mm] In Stent Re
More informationPCI for Left Main Coronary Artery Stenosis. Jean Fajadet Clinique Pasteur, Toulouse, France
PCI for Left Main Coronary Artery Stenosis Jean Fajadet Clinique Pasteur, Toulouse, France Athens, October 19, 2018 Left Main Coronary Artery Disease Significant unprotected left main coronary artery disease
More informationIan T. Meredith AM. MBBS, PhD, FRACP, FCSANZ, FACC, FSCAI, FAPSIC MonashHeart, Monash Medical Centre & Monash University Melbourne, Australia
Final five-year clinical outcomes in the EVOLVE trial: A randomised evaluation of a novel bioabsorbable polymer-coated, everolimus-eluting stent Ian T. Meredith AM MBBS, PhD, FRACP, FCSANZ, FACC, FSCAI,
More informationThe jailed side branch and OCT guided cross over. Accidental abluminal rewiring, OCT check or optimal technique?
Friday October 18th EBC 2013 FINAL PROGRAMME Morning 09:00-09:30 EBC board meeting 09:30-11:30 Abbott meeting with EBC Board 10:30-12:30 St Jude Medical pre-meeting 12:00 13:00 - WELCOME LUNCH PARALLEL
More informationNATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE GUIDANCE EXECUTIVE (GE)
NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE GUIDANCE EXECUTIVE (GE) Review of TA152 drug-eluting stents for the treatment of coronary artery disease (part review of TA71) this guidance was originally
More informationXIENCE Sierra INTRODUCING
INTRODUCING Sierra With the safety you ve always relied on and the deliverability you ve always wanted, choosing the right stent is now an easier decision. START 2017 Abbott. All rights reserved. AP2944678-OUS
More informationSession: EBC s position on dedicated devices. Pro
Session: EBC s position on dedicated devices Pro Robert J. Gil 1,2, MD, PhD, FESC 1- Mossakowski Medical Research Centre, Polish Academy of Sciences 2- Invasive Cardiology Dept., Central Hospital of the
More informationUltimaster clinical results in left main and bifurcations
Left main and complex bifurcation stenting clinical results in left main and bifurcations GENNARO SARDELLA MD, FACC,FESC O.U. of Interventional Cardiology Dept. of Cardiovascular and Pulmonary Sciences
More informationSCAAR: Lower late and very late stent thrombosis rates with new generation drug eluting stents compared to bare metal stents
SCAAR: Lower late and very late stent thrombosis rates with new generation drug eluting stents compared to bare metal stents Christoph Varenhorst, Giovanna Sarno, Göran Olivecrona, Per Tornvall, Johan
More informationHCS Working Group Seminars Macedonia Pallas Hotel, Friday 21 st February Drug-eluting stents Are they all equal?
HCS Working Group Seminars Macedonia Pallas Hotel, Friday 21 st February 2014 Drug-eluting stents Are they all equal? Vassilis Spanos Interventional Cardiologist, As. Director 3 rd Cardiology Clinic Euroclinic
More informationNobori Clinical Studies Up-dates. Gian Battista DANZI, M.D. Ospedale Maggiore Policlinico University of Milan, Italy
Nobori Clinical Studies Up-dates Gian Battista DANZI, M.D. Ospedale Maggiore Policlinico University of Milan, Italy Drug Eluting Stents High benefit in preventing restenosis and improving quality of life
More informationSupplementary Material to Mayer et al. A comparative cohort study on personalised
Suppl. Table : Baseline characteristics of the patients. Characteristic Modified cohort Non-modified cohort P value (n=00) Age years 68. ±. 69.5 ±. 0. Female sex no. (%) 60 (0.0) 88 (.7) 0.0 Body Mass
More informationBioresorbable polymer drug-eluting stents in PCI
EARN 3 FREE CPD POINTS CARDIOVASCULAR Leader in digital CPD for Southern African healthcare professionals The BIOFLOW-V trial, using the Orsiro ultrathin strut stent with biodegradable polymer, showed
More informationLM stenting - Cypher
LM stenting - Cypher Left main stenting with BMS Since 1995 Issues in BMS era AMC Restenosis and TLR (%) 3 27 TLR P=.282 Restenosis P=.71 28 2 1 15 12 Ostium 5 4 Shaft Bifurcation Left main stenting with
More informationLisette Okkels Jensen
A Randomized Trial Comparing a Polymer- Free Coronary Drug-Eluting Stent With an Ultra-Thin Strut Bioresorbable Polymer- Based Drug-Eluting Stent in an All-Comers Patient Population Lisette Okkels Jensen
More informationSafety of Drug-Eluting Stents in Acute Coronary Syndromes
Rotterdam, June 11 th 2012 Safety of Drug-Eluting Stents in Acute Coronary Syndromes Stephan Windecker Department of Cardiology Swiss Cardiovascular Center and Clinical Trials Unit Bern Bern University
More informationEvolution In Interventional Cardiology. Jawed Polad Jeroen Bosch Hospital s-hertogenbosch The Netherlands
Evolution In Interventional Cardiology Jawed Polad Jeroen Bosch Hospital s-hertogenbosch The Netherlands 25 November 2010 Coronary Atherosclerosis Timeline in interventional cardiology Indications for
More informationDrug Eluting Stents Sometimes Fail ESC Stockholm 29 Set 2010 Stent Thrombosis Alaide Chieffo
Drug Eluting Stents Sometimes Fail ESC Stockholm 29 Set 2010 Stent Thrombosis 11.45-12.07 Alaide Chieffo San Raffaele Scientific Institute, Milan, Italy Historical Perspective 25 20 15 10 5 0 Serruys 1991
More information1/22/2017. Ultimaster Clinical evidence. Hazem Khamis,MD,FACC October 6 University Egypt
Ultimaster Clinical evidence Hazem Khamis,MD,FACC October 6 University Egypt Vienna November 2012 1 2 IC-215303-AA JAN2014 5 of 25 IC-215303-AA JAN2014 6 of 25 1/22/2017 Key Elements of Stent for Complex
More informationBIOFREEDOM: Polymer free Biolimus A9 eluting
TCTAP 2011 Seoul, April 27 29, 2011 BIOFREEDOM: Polymer free Biolimus A9 eluting Stents and Paclitaxel eluting stents Eberhard Grube MD, FACC, FSCAI Hospital Oswaldo Cruz - Dante Pazzanese, São Paulo,
More informationDrug Eluting Stents: Bifurcation and Left Main Approach
TCT Asia 2006 Drug Eluting Stents: Bifurcation and Left Main Approach Eberhard Grube MD FACC, FSCAI Heart Center,, Germany Stanford University, School of Medicine, CA, USA DES in High Risk Lesions TAXUS
More informationUnprotected left main coronary stenting with a second generation drug-eluting stent. One-year clinical follow-up of the LeMaX pilot study.
Unprotected left main coronary stenting with a second generation drug-eluting stent. One-year clinical follow-up of the LeMaX pilot study. N. Boudou, N. Salvatella, N. Dumonteil, M.C. Morice, O. Darremont,
More informationTechnical considerations in the Treatment of Left Main Lesions Ioannis Iakovou, MD, PhD
Technical considerations in the Treatment of Left Main Lesions Ioannis Iakovou, MD, PhD Onassis Cardiac Surgery Center, Athens, Greece Critical issues in LM PCI Anatomic variability Techniques Variability
More informationUnprotected LM intervention
Unprotected LM intervention Guideline for COMBAT Seung-Jung Park, MD, PhD Professor of Internal Medicine, Seoul, Korea Current Recommendation for unprotected LMCA Stenosis Class IIb C in ESC guideline
More informationThe BIO revolution: bioadsorbable stents. Federico Conrotto Cardiologia 2 Città della Salute e della Scienza di Torino
The BIO revolution: bioadsorbable stents Federico Conrotto Cardiologia 2 Città della Salute e della Scienza di Torino BVS stent (Abbot Vascular) Strut Material: Poly-L-Lactic acid Coating Material: Poly-D,L-lactide
More informationBifurcation stenting with BVS
Bifurcation stenting with BVS Breaking the limits or just breaking the struts? Maciej Lesiak Department of Cardiology University Hospital in Poznan, Poland Disclosure Speaker s name: Maciej Lesiak I have
More informationCARDIOLOGY NEWSLETTER
CARDIOLOGY NEWSLETTER Congress and Events PCR London Valves Webcast: The ACURATE neo TAVI System, symplifying TAVI procedures Short DAPT Trial with SYNERGY BP Stent: Superior outcomes in Elderly Patients
More informationBiolimus-Eluting Stent With Biodegradable Polymer Versus Sirolimus-Eluting Stent With Durable Polymer: A Randomised, Non-Inferiority Trial
Limus Eluted From A Durable vs ERodable Stent Coating Biolimus-Eluting Stent With Biodegradable Polymer Versus Sirolimus-Eluting Stent With Durable Polymer: A Randomised, Non-Inferiority Trial Stephan
More informationDrug eluting stents. Where are we now and what can we expect in 2003? Tony Gershlick Leicester
Drug eluting stents Where are we now and what can we expect in 2003? Tony Gershlick Leicester Trials Real World What we need i. Prevent restenosis cost effective Either : - Treat all at equivalent cost
More informationSKG Congress, 2015 EVOLVE II. Stephan Windecker
SKG Congress, 2015 EVOLVE II Stephan Windecker Department of Cardiology Swiss Cardiovascular Center and Clinical Trials Unit Bern Bern University Hospital, Switzerland BIODEGRADABLE POLYMER DES Stefanini,
More informationSee the key highlights of Boston Scientific at EuroPCR2016:
InTouch Cardiology Newsletter Issue 1 InTouch Advanced Collaborative Services Congresses and Events See the key highlights of Boston Scientific at EuroPCR2016:» Boston Scientific announces long-term data
More informationPROMUS Element Experience In AMC
Promus Element Luncheon Symposium: PROMUS Element Experience In AMC Jung-Min Ahn, MD. University of Ulsan College of Medicine, Heart Institute, Asan Medical Center, Seoul, Korea PROMUS Element Clinical
More informationEconomic evaluation of sirolimus-eluting stents Shrive F M, Manns B J, Galbraith P D, Knudtson M L, Ghali W A
Economic evaluation of sirolimus-eluting stents Shrive F M, Manns B J, Galbraith P D, Knudtson M L, Ghali W A Record Status This is a critical abstract of an economic evaluation that meets the criteria
More informationInnovation in Cardiovascular Interventions. New DES, Scaffolds and other Devices Have Angioplasty Results Improved
Innovation in Cardiovascular Interventions New DES, Scaffolds and other Devices Have Angioplasty Results Improved Alexandra Lansky, MD Yale University School of Medicine University College of London DES
More informationSession: DEB their Utility. Innovation in Drug Coated Balloons
Session: DEB their Utility 2 nd MARCH 2014 Innovation in Drug Coated Balloons Dr. Upendra Kaul Fortis Escorts Heart Institute New Delhi Disclosure I, Upendra Kaul, do not have a financial interest/arrangement
More informationPercutaneous coronary intervention in left main disease: SYNTAX, PRECOMBAT, EXCEL and NOBLE combined cardiology and cardiac surgery perspective
Perspective Percutaneous coronary intervention in left main disease: SYNTAX, PRECOMBAT, EXCEL and NOBLE combined cardiology and cardiac surgery perspective Duk-Woo Park 1, Jung-Min Ahn 1, Seung-Jung Park
More informationA Paclitaxel-Eluting Balloon for Bifurcation Lesions : Early Clinical Observations
Innovative Devices : Non Stent Technologies : Drug Eluting Balloons A Paclitaxel-Eluting Balloon for Bifurcation Lesions : Early Clinical Observations Pieter R. Stella, MD Director CardioVascular Research
More informationSupplementary appendix
Supplementary appendix This appendix formed part of the original submission and has been peer reviewed. We post it as supplied by the authors. Supplement to: Byrne RA, Stone GW, Ormiston J, Kastrati A.
More informationAdditional Contributor: Glenn Levine (USA).
2017 ESC Focused Update on Dual Antiplatelet Therapy in Coronary Artery Disease developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS) The Task Force for the Management
More informationSupplementary Online Content
Supplementary Online Content Valle JA, Tamez H, Abbott JD, et al. Contemporary use and trends in unprotected left main coronary artery percutaneous coronary intervention in the United States: an analysis
More informationThe MAIN-COMPARE Study
Long-Term Outcomes of Coronary Stent Implantation versus Bypass Surgery for the Treatment of Unprotected Left Main Coronary Artery Disease Revascularization for Unprotected Left MAIN Coronary Artery Stenosis:
More informationSummary HTA. Drug-eluting stents vs. coronary artery bypass-grafting. HTA-Report Summary. Gorenoi V, Dintsios CM, Schönermark MP, Hagen A
Summary HTA HTA-Report Summary Drug-eluting stents vs. coronary artery bypass-grafting in coronary heart disease Gorenoi V, Dintsios CM, Schönermark MP, Hagen A Scientific background The coronary heart
More informationEXPERIENCE MAGIC IN ITS TOUCH
EXPERIENCE MAGIC IN ITS TOUCH SCOPE OF DEB WHY SIROLIMUS? DES restenosis + COMPARISON OF Very Late Thrombosis Long DAPT Therapy Attribute Limus Paclitaxel Small Vessels Bifurcation Lesions Acute Myocardial
More informationWill Bioresorbable Scaffolds Change How We Think About Left Main PCI?
TCT 2014 13 Sep 2014-17 Sep 2014, Washington, DC - U.S.A Will Bioresorbable Scaffolds Change How We Think About Left Main PCI? Robert-Jan van Geuns, MD, PhD Professor of Interventional Cardiology, Thoraxcenter,
More informationIntroduction. Original Article
Original Article Clinical performance of a novel ultrathin strut, low-dose, sirolimuseluting stent with abluminal-only biodegradable polymeric coating for patients undergoing percutaneous coronary intervention
More informationLe# main treatment with Stentys stent. Carlo Briguori, MD, PhD Clinica Mediterranea Naples, Italy
Le# main treatment with Stentys stent Carlo Briguori, MD, PhD Clinica Mediterranea Naples, Italy Disclosure Statement of Financial Interest I, Carlo Briguori DO NOT have a financial interest/ arrangement
More informationInterventional cardiology has made great strides in
STEPHEN G. ELLIS, MD Department of Cardiovascular Medicine, Heart and Vascular Institute, Cleveland Clinic HARIS RIAZ, MD Resident, Department of Internal Medicine, Cleveland Clinic Bioresorbable stents:
More informationPolymer-free Drug-Coated Coronary Stents in Patients at High Bleeding Risk
The new england journal of medicine Original Article Polymer-free Drug-Coated Coronary s in Patients at High Bleeding Risk Philip Urban, M.D., Ian T. Meredith, M.B., B.S., Ph.D., Alexandre Abizaid, M.D.,
More informationThree-Year Clinical Outcomes with Everolimus-Eluting Bioresorbable Scaffolds: Results from the Randomized ABSORB III Trial Stephen G.
Three-Year Clinical Outcomes with Everolimus-Eluting Bioresorbable Scaffolds: Results from the Randomized ABSORB III Trial Stephen G. Ellis MD Dean J. Kereiakes MD and Gregg W. Stone MD for the ABSORB
More information2-Year Patient-Related Versus Stent-Related Outcomes
Journal of the American College of Cardiology Vol. 60, No. 13, 2012 2012 by the American College of Cardiology Foundation ISSN 0735-1097/$36.00 Published by Elsevier Inc. http://dx.doi.org/10.1016/j.jacc.2012.07.004
More informationThe SORT OUT VI Trial
A Prospective, Randomized, "All-Comers" Trial of Biodegradable Polymer-Coated Biolimus-Eluting Stents vs. Biocompatible Polymer-Coated Zotarolimus-Eluting Stents The SORT OUT VI Trial Bent Raungaard, Lisette
More informationBALLROOM C BALLROOM B SENTRAL BALLROOM Emcee : Chairpersons: Panelists: Updates on MySTEMI Network towards an Ideal STEMI network
MY LIVE 2016 DAY 1: THURSDAY 28 th July 2016 BALLROOM C BALLROOM B SENTRAL BALLROOM Emcee : 0830-0900 0900-0930 0930-1000 MyLive 15: 1 year outcomes of cases Welcome Address, Opening Ceremony and Sponsors
More informationWhat s New in Antiplatelet Therapy and DES in 2016
What s New in Antiplatelet Therapy and DES in 2016 Peter Pollak MD Director of Structural Heart Disease & Intervention Mayo Clinic Florida 2016 slide-1 Disclosures Financial None Off-label - None 2016
More informationPOLish Bifurcation Optimal treatment Strategy randomized Study (POLBOSS) - Interim analysis
POLish Bifurcation Optimal treatment Strategy randomized Study (POLBOSS) - Interim analysis Robert J. Gil 1,2, MD, PhD, FESC 1- Mossakowski Medical Research Centre, Polish Academy of Sciences 2- Invasive
More informationEulogio Garcia MD H. U. Gregorio Marañon Madrid
Eulogio Garcia MD H. U. Gregorio Marañon Madrid Coronary Bifurcation Lesions Open Issues Technically demanding Time consuming Low tech success rate Too much operator dependant Off-the the-shelf standard
More informationDrug Eluting Stents overhyped, overused and overpriced?
Advanced Angioplasty 2008 BCIS 23 rd Jan 2008 Drug Eluting Stents overhyped, overused and overpriced? William Wijns MD, PhD Cardiovascular Center Aalst http://www.cardio-aalst.be William.Wijns@village.uunet.be
More information1. Whether the risks of stent thrombosis (ST) and major adverse cardiovascular and cerebrovascular events (MACCE) differ from BMS and DES
1 Comparison of Ischemic and Bleeding Events After Drug- Eluting Stents or Bare Metal Stents in Subjects Receiving Dual Antiplatelet Therapy: Results from the Randomized Dual Antiplatelet Therapy (DAPT)
More informationRandomized comparison of a sirolimus-eluting stent with a biolimus-eluting stent in patients treated with PCI: the SORT OUT VII trial
euro P C R Randomized comparison of a sirolimuseluting stent with a biolimuseluting stent in patients treated with PCI: the SORT OUT VII trial Lisette Okkels Jensen, Per Thayssen, Michael Maeng, Jan Ravkilde,
More informationDRUG ELUTING STENTS. Cypher Versus Taxus: Are There Differences? Introduction. Methods SIGMUND SILBER, M.D., F.E.S.C., F.A.C.C.
DRUG ELUTING STENTS Cypher Versus Taxus: Are There Differences? SIGMUND SILBER, M.D., F.E.S.C., F.A.C.C. From the Cardiology Practice and Hospital, Munich, Germany Today, drug-eluting stents (DES) are
More informationCover Page. The handle holds various files of this Leiden University dissertation
Cover Page The handle http://hdl.handle.net/1887/21543 holds various files of this Leiden University dissertation Author: Dharma, Surya Title: Perspectives in the treatment of cardiovascular disease :
More informationBiolimus-eluting stent with biodegradable polymer: one step forward in the fight against stent thrombosis vulnerability?
Device Evaluation Biolimus-eluting stent with biodegradable polymer: one step forward in the fight against stent thrombosis vulnerability? Drug-eluting stents (DES) were developed to cope with the major
More informationSunao Nakamura M.D,Ph.D.
Drug Eluting Stent Implantation For Unprotected Left ain Coronary Arteries New Tokyo Circulation Research Group New Tokyo Hospital Sunao Nakamura.D,Ph.D. Drug-Eluting Stent for Left ain Coronary Artery
More informationCOMPLEX CASES: LEFT MAIN
COMPLEX CASES: LEFT MAIN Resolute Onyx DES Together are trademarks of Medtronic. * Third-party brands are trademarks of For distribution only in markets where the Resolute Onyx coronary stent has been
More informationOptimal Revascularization in Multivessel Disease and Coronary CTO. Dr Simon Walsh MD FRCP FSCAI Consultant Cardiologist Belfast Trust
Optimal Revascularization in Multivessel Disease and Coronary CTO Dr Simon Walsh MD FRCP FSCAI Consultant Cardiologist Belfast Trust Potential Conflicts of Interest Speaker's name: Simon Walsh Consulting
More informationDrug eluting balloon for bifurcation lesion: is it useful?
Welcome to the 8 th European Bifurcation Club 12-13 October 2012 - Barcelona Drug eluting balloon for bifurcation lesion: is it useful? Dr. Bruno Garcia Hospital Universitari Vall Hebrón Barcelona (Spain)
More informationBiolimus A9 Drug-Eluting Stents: Technical Aspects and a Comprehensive Review of the EU, Asia-Pacific, and US Clinical Trial Program
TCT Asia 2006 Biolimus A9 Drug-Eluting Stents: Technical Aspects and a Comprehensive Review of the EU, Asia-Pacific, and US Clinical Trial Program Eberhard Grube MD FACC, FSCAI HELIS Heart Center Siegburg,
More informationLeft Main and Bifurcation Summit I. Lessons from European LM Studies
Left Main and Bifurcation Summit I Apr 29 8.56-9.09 Lessons from European LM Studies Alaide Chieffo, MD S. Raffaele Hospital, Milan, Italy Nothing to disclose regarding this presentation Lesion Location
More information54B Subject Index - Innovation in Intervention: i2 Summit 2007J jacc March 6, 2007
54B Subject Index - Innovation in Intervention: i2 Summit 2007J jacc March 6, 2007 Subject Index Ablation-catheter Adenosine Adverse Events/cardiovascular care Predictors of Major Vascular Complications
More informationIndex. Note: Page numbers of article titles are in boldface type.
Cardiol Clin 24 (2006) 299 304 Index Note: Page numbers of article titles are in boldface type. A Abciximab in PCI, 180 182 ACE trial, 182 Actinomycin D-eluting stent, 224 ACUITY trial, 190 Acute myocardial
More informationInspiron Stent. Clinical Research Program. Pedro A. Lemos MD PhD. Heart Institute InCor University of Sao Paulo Medical School Sao Paulo Brazil
Stent Clinical Research Program Pedro A. Lemos MD PhD Heart Institute InCor University of Sao Paulo Medical School Sao Paulo Brazil All faculty disclosures are available on the CRF Events App and online
More informationPathology of percutaneous interventions (PCI) in coronary arteries. Allard van der Wal, MD.PhD; Pathologie AMC, Amsterdam, NL
Pathology of percutaneous interventions (PCI) in coronary arteries Allard van der Wal, MD.PhD; Pathologie AMC, Amsterdam, NL Percutaneous Coronary Intervention (PCI) Definition: transcatheter opening of
More informationBIOFLOW by Orsiro stents
BIOFLOW by stents Byeong-Keuk Kim, MD, PhD Division of Cardiology, Department of Internal Medicine, Severance Cardiovascular Hospital, Yonsei University College of Medicine Key Benefits Clinically proven
More informationWhat Stent to Use? JASVINDAR SINGH MD, FACC
What Stent to Use? JASVINDAR SINGH MD, FACC ASSOCIATE PROFESSOR OF MEDICINE WASHINGTON UNIVERSITY IN ST. LOUIS DIRECTOR, CARDIAC CATHETERIZATION LAB BARNES-JEWISH HOSPITAL What Stent to Use? Jasvindar
More informationPresent & future of below the knee stenting
Session 5 Below the knee arteries & limb salvage Present & future of below the knee stenting M. Bosiers K. Deloose P. Peeters 1 PRESENT Clinical perspective whom to treat CRITICAL LIMB ISCHEMIA (CLI) 0
More informationMid-term results from real-world REPARA registry. Felipe Hernandez, on behalf of the REPARA investigators
Mid-term results from real-world REPARA registry Felipe Hernandez, on behalf of the REPARA investigators Potential conflicts of interest Speaker's name: Felipe Hernandez I have the following potential
More informationWelcome to the 8 th European Bifurcation Club October Barcelona
Welcome to the 8 th European Bifurcation Club 12-13 October 2012 - Barcelona Safety and clinical efficacy of Sideguard stent for treatment of bifurcation lesions Interim results from European multicentre
More informationClinical Study Age Differences in Long Term Outcomes of Coronary Patients Treated with Drug Eluting Stents at a Tertiary Medical Center
Aging Research Volume 2013, Article ID 471026, 4 pages http://dx.doi.org/10.1155/2013/471026 Clinical Study Age Differences in Long Term Outcomes of Coronary Patients Treated with Drug Eluting Stents at
More informationAnticoagulants and antiplatelet therapy in the older patient: Choosing wisely
Anticoagulants and antiplatelet therapy in the older patient: Choosing wisely Rajiv Gulati, MD PhD Advances in Cardiac Arrhythmias & Great Innovations in Cardiology Torino, October 2015 2015 MFMER 3477310-1
More informationOCT Technology: Differences between Biodegradable and Durable Polymers: Insights from the LEADERS Trial LEADERS OCT
OCT Technology: Differences between Biodegradable and Durable Polymers: Insights from the LEADERS Trial LEADERS OCT Substudy Carlo Di Mario, MD Peter Barlis, MD Evelyn Regar, MD Peter Juni, MD Patrick
More informationEluNIR. Ridaforolimus Eluting Coronary Stent System. Advancing Deliverability for the Road Ahead
Ridaforolimus Eluting Coronary Stent System Advancing Deliverability for the Road Ahead The Coronary Stent System Raising the Bar on Drug-Eluting Stent Technology Introducing the Coronary Stent System,
More informationContinuing Cardiology Education
Continuing Cardiology Education Stent selection for percutaneous coronary intervention P. D. Williams* & M. Awan James Cook University Hospital, Middlesbrough, United Kingdom Keywords Coronary artery disease,
More informationSTENTYS for Le, Main Sten2ng. Carlo Briguori, MD, PhD Clinica Mediterranea Naples, Italy
STENTYS for Le, Main Sten2ng Carlo Briguori, MD, PhD Clinica Mediterranea Naples, Italy Disclosure Statement of Financial Interest I, Carlo Briguori DO NOT have a financial interest/ arrangement or affilia2on
More information